3680-28-2

Basic information

• Product Name: 7-METHYL-1,3-DIHYDRO-INDOL-2-ONE
• Synonyms: 7-METHYL-1,3-DIHYDRO-INDOL-2-ONE;7-Methyloxindole;7-Methyl-1,3-dihydro-2H-indol-2-one;7-methyl-1,3-dihydro-2H-indol-2-one(SALTDATA: FREE);7-Methyl-2-oxindole;7-Methylindolin-2-one;1,3-Dihydro-7-methyl-2H-indol-2-one;2H-Indol-2-one, 1,3-dihydro-7-methyl-
• CAS NO: 3680-28-2
• Molecular Formula: C₉H₉NO
• Molecular Weight: 147.18
• Mol File: 3680-28-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 307.6°C at 760 mmHg
• Flash Point: 176.3°C
• Appearance: /
• Density: 1.155g/cm³
• Vapor Pressure: 0.000717mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-METHYL-1,3-DIHYDRO-INDOL-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHYL-1,3-DIHYDRO-INDOL-2-ONE(3680-28-2)
• EPA Substance Registry System: 7-METHYL-1,3-DIHYDRO-INDOL-2-ONE(3680-28-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 3680-28-2(Hazardous Substances Data)

Usage

General Description

7-Methyl-1,3-dihydro-indol-2-one is a chemical compound that belongs to the class of indole derivatives. It is a small molecule with the molecular formula C9H9NO, and it is commonly used in research and pharmaceutical applications. 7-METHYL-1,3-DIHYDRO-INDOL-2-ONE has been studied for its potential pharmacological properties, including its role as a building block in the synthesis of various bioactive compounds. Its structure contains a fused indole ring with a methyl group at the 7th position, giving it unique chemical and biological properties. Research on 7-Methyl-1,3-dihydro-indol-2-one continues to explore its potential applications in drug discovery and development.

InChI:InChI=1/C9H9NO/c1-6-3-2-4-7-5-8(11)10-9(6)7/h2-4H,5H2,1H3,(H,10,11)

Upstream product

• 18710-86-6 2-(3-methyl-2-nitrophenyl)acetic acid 
• 95-53-4 o-toluidine 
• 120-66-1 N-(2-methylphenyl)acetamide 
• 623-48-3 ethyl iodoacetae 
• 1127-59-9 7-methyl-1H-indole-2,3-dione 
• 10166-09-3 (o-tolyl)acetyl chloride 
• 121990-15-6 N-chloro-N-methoxy-2-(2-methylphenyl)acetamide 
• 121989-43-3 N-Methoxy-2-o-tolyl-acetamide 
• 121989-50-2 1-Methoxy-7-methyl-1,3-dihydro-indol-2-one 
• 37394-93-7 2-chloro-N-(2-methylphenyl)acetamide 

Downstream Products

• 1127-59-9 7-methyl-1H-indole-2,3-dione 

Relevant articles and documents

Selective formation of γ-lactams via C-H amidation enabled by tailored iridium catalysts

Intramolecular insertion of met al nitrenes into carbon-hydrogen bonds to form γ-lactam rings has traditionally been hindered by competing isocyanate formation. We report the application of theory and mechanism studies to optimize a class of pentamethylcyclopentadienyl iridium(III) catalysts for suppression of this competing pathway. Modulation of the stereoelectronic properties of the auxiliary bidentate ligands to be more electron-donating was suggested by density functional theory calculations to lower the C-H insertion barrier favoring the desired reaction. These catalysts transform a wide range of 1,4,2-dioxazol-5-ones, carbonylnitrene precursors easily accessible from carboxylic acids, into the corresponding γ-lactams via sp3 and sp2 C-H amidation with exceptional selectivity. The power of this method was further demonstrated by the successful late-stage functionalization of amino acid derivatives and other bioactive molecules.

Palladium-Catalyzed C-H Activation and Cyclization of Anilides with 2-Iodoacetates and 2-Iodobenzoates: An Efficient Method toward Oxindoles and Phenanthridones

A concise approach to the synthesis of oxindoles and phenanthridones from anilides is described. In the presence of catalytic amount of Pd(OAc)2, 2-iodoacetates and 2-iodobenzoates can be used to functionalize ortho C-H bond of anilides, which subsequently undergo intramolecular cyclization to give the products. A possible reaction mechanism that involves a PdII/PdIV catalytic cycle is proposed with the support of detailed mechanistic studies.

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.